Form 4: 10X Fund Sells GALT Shares, Maintains Large Stake

10X Fund, a 10% owner and director of Galectin Therapeutics Inc., reported the sale of 40,000 shares of common stock for $5.25 per share.

Summary

• 10X Fund, L.P., identified as a Director and 10% Owner of Galectin Therapeutics Inc. (GALT), reported a transaction.
• On November 11, 2025, 10X Fund, L.P. disposed of 40,000 shares of GALT common stock.
• The shares were sold at a price of $5.25 per share.
• Following this transaction, 10X Fund, L.P. directly beneficially owns 5,832,207 shares of GALT common stock.
• 10X Capital Management, LLC, as the general partner of 10X Fund, L.P., and James C. Czirr, as the manager of 10X Capital Management, LLC, may be deemed to have indirect beneficial ownership but disclaim ownership except to the extent of their pecuniary interest.

Sentiment

Score: 4

Explanation: The sale of shares by a significant insider (10% owner and director) is generally viewed as a negative signal, although the amount sold represents a small fraction of their total holdings, tempering the severity.

Negatives

• A 10% owner and director, 10X Fund, L.P., sold 40,000 shares of common stock, which could be interpreted as a lack of confidence or a move to rebalance their portfolio.

Risks

• Intentional misstatements or omissions of facts constitute Federal Criminal Violations as per 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Future Outlook

The filing does not contain any forward-looking statements or guidance.

Industry Context

This transaction is an insider trading report, reflecting a specific investment decision by a significant shareholder and director. It does not directly provide insights into broader industry trends for Galectin Therapeutics' sector, which typically involves biotechnology and pharmaceutical development.

Related Party Transactions

• 10X Capital Management, LLC is the general partner of 10X Fund, L.P. and may be deemed to have indirect beneficial ownership.
• James C. Czirr is the manager of 10X Capital Management, LLC and may be deemed to have indirect beneficial ownership.

Stakeholder Impact

• Shareholders may interpret the sale by a significant owner as a negative signal, potentially influencing stock price perception.
• The transaction itself does not directly impact employees, customers, suppliers, or creditors, but market reaction could indirectly affect company morale or access to capital.

Key Dates

Recommendation

While an insider sale by a 10% owner is generally a negative signal, the reported transaction represents a relatively small portion of 10X Fund's total holdings in GALT. Without additional context on the company's operational performance or strategic direction, this single transaction is not sufficient to warrant a 'sell' recommendation, but it does introduce a cautionary note, suggesting a 'hold' to observe further developments.

Keywords

Galectin Therapeutics, GALT, 10X Fund, Insider Trading, SEC Form 4, Stock Sale, Beneficial Ownership, Director Transaction, 10% Owner